Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=15113371&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent Firpi RJ; Tran TT; Flores P; Nissen N; Colquhoun S; Shackleton C; Martin P; Vierling JM; Poordad FFAliment Pharmacol Ther 2004[May]; 19 (9): 1033-9BACKGROUND: Sirolimus is a potent immunosuppressive medication that acts by inhibiting T-cell proliferation. It has been used in kidney transplantation because of its lack of nephrotoxicity. It is now being investigated in liver transplantation, but there are concerns about safety and long-term side effects such as dyslipidaemia. Hypertriglyceridaemia is a common adverse event seen with sirolimus use, and often does not respond to dose reduction or anti-lipemic drugs. METHOD: We report six patients who have developed significant hyperlipidaemia while receiving sirolimus, in spite of therapeutic trough levels. CONCLUSION: All six patients showed either resolution or improvement in lipid levels with discontinuation of sirolimus.|*Kidney Transplantation[MESH]|Adult[MESH]|Aged[MESH]|Cyclosporine/therapeutic use[MESH]|Dose-Response Relationship, Drug[MESH]|Drug Therapy, Combination[MESH]|Female[MESH]|Humans[MESH]|Hyperlipidemias/*chemically induced[MESH]|Immunosuppressive Agents/*adverse effects[MESH]|Male[MESH]|Middle Aged[MESH]|Sirolimus/*adverse effects[MESH]|Tacrolimus/therapeutic use[MESH] |
